Amgen announces plans for the construction of new manufacturing facility. The new plant will be dedicated in manufacturing medicines to treat serious illnesses such as cancer and heart disease.
The new manufacturing facility will be added to the existing robust biomanufacturing ecosystem. It ensures to produce wide range of medicines to patients by making use of new technologies to maximize efficiency and quality.
The new facility will meet the exacting environmental standards, reduces water usage by 40 percent and waste by 75 percent and becoming carbon neutrality by 2027. Moreover, the plant evolves as a major hub for biopharmaceutical innovation.
Currently it has manufacturing facilities in California, Ireland, Netherlands, Ohio, Puerto Rico, Rhode Island and Singapore.
The construction of the new facility is expected to be completed and fully operational by 2025.
The site already consists of 24,000 employees worldwide and the new facility is expected to add an additional 350 high-quality new jobs.